scispace - formally typeset
S

Saad A. Khan

Researcher at University of Texas Southwestern Medical Center

Publications -  63
Citations -  2673

Saad A. Khan is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 14, co-authored 53 publications receiving 1399 citations.

Papers
More filters
Journal ArticleDOI

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

Barbara Burtness, +205 more
- 23 Nov 2019 - 
TL;DR: A randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries finds that pembrolizumab alone improved overall survival and progression-free survival and cetuximab with chemotherapy improved Overall survival in the total population.
Journal ArticleDOI

Immune dysregulation in cancer patients developing immune-related adverse events.

TL;DR: Patients who developed irAEs have lower baseline levels and greater post-treatment increases in multiple cytokine levels, suggesting that underlying immune dysregulation may be associated with heightened risk for irAE’s.
Journal ArticleDOI

Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks.

TL;DR: Head and neck cancer patients are generally at high-risk for COVID-19 infection and severe adverse outcomes, and urgent guidance in the delivery of safe, quality head and neck oncologic care is needed.
Journal ArticleDOI

Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer

TL;DR: FDG PET/CT is a valuable imaging tool for identifying unknown primary tumors in patients with known cervical node metastases leading to management change and is the standard of care for the initial staging of stage III and IV head and neck squamous cell carcinomas.